April 25th 2024
Despite a wealth of knowledge, pharmacists are frequently not consulted as part of the decision-making team in atrial fibrillation management.
Continuing the Conversation: Considerations for Pharmacists to Individualize DOAC Therapy
May 29, 2024 | 1:00 PM ET
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Recent Advances in Omega-3 Fatty Acids to Reduce Risk of ASCVD in Patients With Elevated Triglyceride Levels
0.75 Credit / Cardiology
View More
Introduction to Anticoagulation and the Appropriate Patient
1.0 Credit / Cardiology
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
The Treatment Landscape and a Review of Approved DOAC Agents
1.0 Credit / Cardiology
View More
Maximizing Patient Outcomes Through Pharmacist-Led Homozygous Familial Hypercholesterolemia Management
1.0 Credit / Cardiology
View More
Setting the Stage: An Introduction to Worsening Heart Failure Events in Patients With Heart Failure With Reduced Ejection Fraction
1.0 Credit / Cardiology
View More
Navigating the Therapeutic Landscape of Homozygous Familial Hypercholesterolemia
1.0 Credit / Cardiology
View More
Understanding the Challenges of Homozygous Familial Hypercholesterolemia
1.0 Credit / Cardiology
View More
The Role of the Pharmacist in Optimizing DOAC Utilization Across Practice Settings
1.0 Credit / Cardiology
View More
Soluble Guanylate Cyclase Stimulators in the Management of Worsening Heart Failure With Reduced Ejection Fraction
1.0 Credit / Cardiology
View More
Individualizing Care for Patients With Heart Failure: The Role of the Pharmacist in Optimizing Education and Improving Adherence
1.0 Credit / Cardiology
View More
Advancing Chronic Worsening Heart Failure Treatment: The Critical Role of Pharmacists in Therapy Integration
1.0 Credit / Cardiology
View More
Iron Deficiency and Anemia in Heart Failure: Clinical Applications for the Use of Intravenous Iron
1.5 Credits / Cardiology
View More
Advances and Best Practices for Managed Care Pharmacists in the Treatment of Heart Failure with Preserved Ejection Fraction
1.0 Credits / Cardiology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
FDA OKs Dapagliflozin for Heart Failure With Reduced Ejection Fraction
May 6th 2020Officials with the FDA have approved dapagliflozin (Farxiga, AstraZeneca) to reduce the risk of cardiovascular death and hospitalization in adults with heart failure with reduced ejection fraction, with and without type 2 diabetes.